Immunovant Stock Buy Hold or Sell Recommendation

IMVT -  USA Stock  

USD 8.21  0.09  1.08%

Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Immunovant is 'Hold'. Macroaxis provides Immunovant buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding IMVT positions. The advice algorithm takes into account all of Immunovant's available fundamental, technical, and predictive indicators you will find on this site.

Immunovant Advice 

 
Refresh
The advice is provided from Immunovant's buy-and-hold perspective. Please see Immunovant Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Immunovant and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Immunovant.

Execute Immunovant Buy or Sell Advice

The Immunovant recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Immunovant. Macroaxis does not own or have any residual interests in Immunovant or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Immunovant's advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell ImmunovantBuy Immunovant
Hold

Volatility

Somewhat reliableDetails

Hype Condition

Over hypedDetails

Current Valuation

UndervaluedDetails

Odds of Distress

Quite HighDetails

Economic Sensitivity

Follows the market closelyDetails

Analyst Consensus

BuyDetails

Financial Strenth (F Score)

FrailDetails

Financial Leverage

InapplicableDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Immunovant has a Risk Adjusted Performance of (0.022726), Jensen Alpha of (0.21), Total Risk Alpha of (0.34) and Treynor Ratio of (0.36)
We provide advice to complement the regular expert consensus on Immunovant. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Immunovant is not overpriced, please check out all Immunovant fundamentals, including its shares owned by institutions, cash per share, as well as the relationship between the Cash per Share and short ratio . Given that Immunovant has a cash and equivalents of 379 M, we strongly advise you to confirm Immunovant market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Immunovant Trading Alerts and Improvement Suggestions

Immunovant generated a negative expected return over the last 90 days
Immunovant has high historical volatility and very poor performance
Immunovant has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (111.19 M).
Immunovant currently holds about 379 M in cash with (90.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.3.
Immunovant has a frail financial position based on the latest SEC disclosures
Roughly 65.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Acquisition by Barnett Eva Renee of 333000 shares of Immunovant subject to Rule 16b-3

Immunovant current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunovant analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunovant analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Mean Price18.00
Target Median Price19.00
Target High Price32.00
Recommendation Mean2.40
Number Of Analyst Opinions7
Target Low Price7.00
Average Consensus Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Immunovant Returns Distribution Density

The distribution of Immunovant's historical returns is an attempt to chart the future uncertainty of Immunovant's future price movements. The chart of the probability distribution of Immunovant stock daily returns describes the distribution of returns around its average expected value. We use Immunovant price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Immunovant returns is essential to provide solid investment advice for Immunovant stock.
Mean Return-0.19Value At Risk-5.42
Potential Upside4.99Standard Deviation4.35
 Return Density 
      Distribution 
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Immunovant historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Immunovant Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Immunovant or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Immunovant stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Immunovant stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over DOW
-0.21
β
Beta against DOW0.57
σ
Overall volatility
4.39
Ir
Information ratio -0.05

Immunovant Volatility Alert

Immunovant exhibits very low volatility with skewness of -3.27 and kurtosis of 18.58. However, we advise investors to further study Immunovant technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Immunovant's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Immunovant's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Immunovant Fundamentals Vs Peers

Comparing Immunovant's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Immunovant's direct or indirect competition across all of the common fundamentals between Immunovant and the related equities. This way, we can detect undervalued stocks with similar characteristics as Immunovant or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Immunovant's fundamental indicators could also be used in its relative valuation, which is a method of valuing Immunovant by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Immunovant to competition
FundamentalsImmunovantPeer Average
Return On Equity(35.12) %(0.31) %
Return On Asset(20.53) %(0.14) %
Current Valuation638.34 M16.62 B
Shares Outstanding97.97 M571.82 M
Shares Owned by Insiders65.13 %10.09 %
Shares Owned by Institutions33.64 %39.21 %
Number of Shares Shorted4.28 M4.71 M
Price to Book2.17 X9.51 X
EBITDA(111.34 M)3.9 B
Net Income(111.19 M)570.98 M
Cash and Equivalents379 M2.7 B
Cash per Share3.30 X5.01 X
Total Debt3.06 M5.32 B
Debt to Equity0.008 %48.70 %
Current Ratio18.75 X2.16 X
Book Value Per Share3.73 X1.93 K
Cash Flow from Operations(90.74 M)971.22 M
Short Ratio5.41 X4.00 X
Earnings Per Share(1.18) X3.12 X
Number of Employees6818.84 K
Market Capitalization813.16 M19.03 B
   Acquisition by Barnett Eva Renee of 333000 shares of Immunovant subject to Rule 16b-3 [view details]

About Immunovant Buy or Sell Advice

When is the right time to buy or sell Immunovant? Buying financial instruments such as Immunovant Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Although Immunovant investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2010 2019 2020 2021 (projected)
Current Assets12.58 M109.08 M409.01 M441.3 M
Total Assets13.83 M109.39 M412.49 M445.05 M

Use Investing Ideas to Build Portfolios

In addition to having Immunovant in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Food Products Thematic Idea Now

Food Products
Food Products Theme
Fama and French focuses on testing asset pricing under different economic assumptions. Food Products theme has 36 constituents.
View All  Next Launch Food Products
Please see Immunovant Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the Immunovant information on this page should be used as a complementary analysis to other Immunovant's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Immunovant Stock analysis

When running Immunovant price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Is Immunovant's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunovant. If investors know Immunovant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunovant listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunovant is measured differently than its book value, which is the value of Immunovant that is recorded on the company's balance sheet. Investors also form their own opinion of Immunovant's value that differs from its market value or its book value, called intrinsic value, which is Immunovant's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunovant's market value can be influenced by many factors that don't directly affect Immunovant's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunovant's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunovant value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunovant's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.